Watson, Daiichi Sankyo, sanofi-aventis metabolic news

Daiichi and sanofi-aventis' Genzyme Corp. subsidiary filed suit against Watson in the U.S. District Court for the District of Delaware alleging that Watson's ANDA for generic colesevelam tablets infringes U.S. Patent Nos. 5,607,669 and 5,693,675 covering hypercholesterolemia drug Welchol colesevelam from Daiichi. The ANDA contains a Paragraph IV notification that the '669 and '675 patents are invalid, unenforceable and/or will not be infringed by the approval or sale of Watson's generic. The plaintiffs are seeking to prevent the approval and sale of Watson's generic before the '669 and '675 patents expire. FDA granted pediatric exclusivity to Welchol, which extends patent protection to June 2, 2015. ...